Stifel Financial Corp trimmed its holdings in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 46.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 337,158 shares of the company's stock after selling 287,718 shares during the period. Stifel Financial Corp owned about 0.41% of Editas Medicine worth $428,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Editas Medicine during the fourth quarter worth approximately $303,000. Barclays PLC increased its holdings in shares of Editas Medicine by 46.9% in the 3rd quarter. Barclays PLC now owns 178,507 shares of the company's stock valued at $607,000 after acquiring an additional 56,986 shares during the last quarter. Monaco Asset Management SAM purchased a new position in shares of Editas Medicine in the 4th quarter valued at about $1,359,000. XTX Topco Ltd boosted its position in shares of Editas Medicine by 99.9% in the 4th quarter. XTX Topco Ltd now owns 105,056 shares of the company's stock valued at $133,000 after purchasing an additional 52,498 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Editas Medicine during the 4th quarter worth approximately $1,843,000. 71.90% of the stock is currently owned by hedge funds and other institutional investors.
Editas Medicine Price Performance
NASDAQ EDIT traded up $0.12 during mid-day trading on Friday, reaching $1.51. 1,603,717 shares of the stock were exchanged, compared to its average volume of 2,578,026. The stock has a market cap of $126.41 million, a P/E ratio of -0.59 and a beta of 2.15. The stock has a 50 day simple moving average of $1.35 and a 200-day simple moving average of $1.64. Editas Medicine, Inc. has a one year low of $0.91 and a one year high of $6.22.
Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.08. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. The business had revenue of $4.66 million for the quarter, compared to analyst estimates of $0.79 million. During the same quarter in the previous year, the firm posted ($76.00) earnings per share. Sell-side analysts anticipate that Editas Medicine, Inc. will post -2.71 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on EDIT shares. StockNews.com raised Editas Medicine from a "sell" rating to a "hold" rating in a research report on Wednesday. HC Wainwright initiated coverage on Editas Medicine in a report on Monday, April 28th. They set a "buy" rating and a $3.00 target price for the company. Robert W. Baird cut their target price on Editas Medicine from $8.00 to $4.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Finally, Cantor Fitzgerald upgraded Editas Medicine from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 29th. Two analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Editas Medicine has an average rating of "Hold" and a consensus target price of $5.36.
Check Out Our Latest Stock Analysis on Editas Medicine
Editas Medicine Profile
(
Free Report)
Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.
Recommended Stories
Before you consider Editas Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.
While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
